What is market sentiment?

Market sentiment is the overall attitude of investors toward a particular security or the financial market as a whole. It reflects whether investors are feeling bullish (optimistic) or bearish (pessimistic) based on price action, news flow, economic indicators, and collective psychology. Kinvestor tracks real-time market sentiment across major indices and individual equities.

How does financial news affect stock prices?

Financial news affects stock prices by shifting investor sentiment. Positive earnings reports, strong economic data, or favorable Fed decisions typically boost stock prices, while negative news can trigger sell-offs. The speed and magnitude of price moves depends on whether the news beats or misses market expectations.

What are stock market movers?

Stock market movers are stocks with significant price changes — either up (gainers) or down (losers) — within a trading session. Movers are typically driven by earnings reports, analyst upgrades or downgrades, macroeconomic news, or major corporate announcements. Kinvestor tracks the biggest movers in real time across the S&P 500, NASDAQ, and Dow Jones.

What is earnings season?

Earnings season is the period each quarter when publicly traded companies report their financial results. It occurs four times per year: January–February (Q4 results), April–May (Q1 results), July–August (Q2 results), and October–November (Q3 results). During earnings season, stocks often experience heightened volatility as results beat or miss analyst expectations.

What is financial intelligence?

Financial intelligence is the ability to understand and interpret financial data, market trends, news, and sentiment to make informed investment decisions. It combines real-time market data, news aggregation, sentiment analysis, and economic indicators into actionable insight. Kinvestor is a financial intelligence platform that aggregates these signals in one place.

◆ NeutralMRKMRNAAZN

Merck Trading Near 52-Week High: Is the Stock a Buy, Hold or Sell?

Zacks Investment Research·September 8, 2026

Merck's stock is trading near its 52-week high, driven by positive phase III data for its Keytruda-Moderna cancer therapy combo and strong fundamentals. Keytruda is expected to reach $35 billion in peak sales by 2028, with the company launching 20 new drugs by 2030. However, Merck faces significant headwinds including Keytruda's 2028 patent expiration, declining Gardasil vaccine sales, and generic erosion of diabetes and other drugs.

Read Full Article at Zacks Investment Research →

← Back to Financial Intelligence